Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta ® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Condition: HER2-positive Breast Cancer Interventions: Drug: TQB2440 injection + Trastuzumab + Docetaxel; Drug: Perjeta + Trastuzumab + Docetaxel Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Conditions: Breast Cancer; Neoadjuvant Therapy Interventions: Drug: Utidelone; Drug: Carboplatin; Drug: Epirubicin; Drug: Trastuzumab; Drug: Pertuzumab Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences Cancer Hospital，Shanxi Center; Chinese Academy of Medical Sciences Cancer Hospital，Shenzhen Center; First Affiliated Hospital of China Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
